Lonza is expanding its collaboration with an American biopharmaceutical company, the identity of which has not been disclosed.
Lonza is expanding its partnership with a US client
Keystone-SDA
Lonza is expanding its collaboration with an American biopharmaceutical company, the identity of which has not been disclosed.
Generated with artificial intelligence.
This content was published on
Lonza expands partnership with US drugmaker, boosts capacity for ADCs
Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases
Swiss pharma faces potential US trade investigation as Washington turns up pressure on drug pricing
Swiss pharmaceutical industry faces potential US trade investigation
Galderma gets CRL for anti-wrinkle drug; Kimball buys CDMO for $103M
Contract manufacturing powerhouse Lonza is growing in more ways than one. | Contract manufacturing powerhouse Lonza is growing in…
Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online…
Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for…
Dans les années à venir, de nombreux brevets protégeant des médicaments vont expirer. Une aubaine pour le groupe bâlois Sandoz,…
Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing…
How Novartis and EPFL built a long-term collaboration grounded in structure and shared ambition.
